Lymphoma Trial, Recruiting (NCT05512169)

Lymphoma Trial, Recruiting NCT05512169 Sponsor: University of Geneva, Switzerland Condition: Lymphoma

Printed from Voxsanity (voxsanity.com.au) — NCT05512169 — Data sourced from ClinicalTrials.gov. Verify directly with the trial site before attending. Not medical advice.

Back to Lymphoma

Who may be able to join

AI generated eligibility summary. Written by an AI model from the official source data and checked on a sample basis. It can contain mistakes, so confirm anything important against the original source. How we use AI

Who might be able to join this trial:

Children and young people who are older than 1 year old and no older than 18 years old at the time of joining the trial
People who have not received any previous treatment for their condition
People whose diagnosis of ALL (a type of blood cancer called Acute Lymphoblastic Leukaemia) has been confirmed through specific laboratory tests looking at cell shape and cell markers
People of Indian origin
People who meet the requirements of the IciCle treatment protocol and are receiving treatment according to that protocol
People for whom a written consent form has been signed by the participant, parent, or guardian agreeing to take part in the study

Who may not be able to join:

People who have already received previous treatment for their condition
People who have Down's syndrome
People whose diagnosis is specifically mature B-ALL (a particular subtype of the condition)

Important: Always verify eligibility with the trial site directly before applying.

Based on publicly available eligibility criteria from ClinicalTrials.gov. Verify directly with the trial site before acting. This is not medical advice.

This is a simplified plain English summary of the eligibility criteria. Full criteria are set by the trial investigators and may include additional requirements not shown here. Never self-exclude from a trial based on this summary. Contact the trial site directly to confirm your eligibility.

Last synced 8 July 2026

This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.

Contact this trial

Principal Investigator: Chakradhara Rao S UPPUGUNDURI, University of Geneva, Switzerland

Phone: +41223794685

Contact details sourced from ClinicalTrials.gov. Verify directly with the trial site before attending.

GP referral letter

Print a one-page summary to share with your doctor.

Voxsanity

Clinical trials and treatments, explained plainly · voxsanity.com.au

Date:

To: My Doctor

Re: Clinical trial enquiry

I am writing to enquire about the following clinical trial which may be relevant to my care:

Trial: NCT05512169

Sponsor: University of Geneva, Switzerland

Phase: Not Applicable

Status: Recruiting

Condition: Lymphoma

Trial contact: +41223794685

More information: https://clinicaltrials.gov/study/NCT05512169

Eligibility summary (AI generated)

Written by an AI model from ClinicalTrials.gov eligibility criteria and checked on a sample basis. Please confirm against the original criteria.

Who might be able to join this trial:

Children and young people who are older than 1 year old and no older than 18 years old at the time of joining the trial
People who have not received any previous treatment for their condition
People whose diagnosis of ALL (a type of blood cancer called Acute Lymphoblastic Leukaemia) has been confirmed through specific laboratory tests looking at cell shape and cell markers
People of Indian origin
People who meet the requirements of the IciCle treatment protocol and are receiving treatment according to that protocol
People for whom a written consent form has been signed by the participant, parent, or guardian agreeing to take part in the study

Who may not be able to join:

People who have already received previous treatment for their condition
People who have Down's syndrome
People whose diagnosis is specifically mature B-ALL (a particular subtype of the condition)

Important: Always verify eligibility with the trial site directly before applying.

Access in Australia: A treatment being studied in a clinical trial is generally not yet listed on the PBS. Where a medicine is not approved or not available through a trial, the TGA Special Access Scheme may allow a doctor to access unapproved therapeutic goods for individual patients. See voxsanity.com.au/sas-navigator/ for a plain English explainer.

This information was sourced from ClinicalTrials.gov via Voxsanity (data last synced 8 July 2026). It is not medical advice. Please verify the trial's current status directly with the trial site before acting.

Trial details

Status

Recruiting

Phase

Not Applicable

Sponsor

University of Geneva, Switzerland

Registry

ClinicalTrials.gov

Start date

1 December 2022

Est. completion

30 March 2027

Where this trial is recruiting

🇮🇳 India

Primary endpoints

Cumulative incidences of early treatment related adverse events as assessed by CTCAE v5.0; Disease response to the treatment during induction phase to steroids; Disease response to the treatment during induction phase

Can't join this trial?

Expanded access pathways

If this trial is not available to you, other access pathways may exist. In Australia, the TGA Special Access Scheme allows access to unapproved therapeutic goods for individual patients.

TGA Special Access Scheme information

Find other recruiting trials on ClinicalTrials.gov

Data last synced from ClinicalTrials.gov: 8 July 2026. Trial status can change. Always verify current status directly with the trial site before making any decision.

Trial recruitment status can change without notice between our nightly data updates. Always contact the trial site directly to confirm current recruitment status before making any decisions or travel arrangements.

View original record on ClinicalTrials.gov